Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Boan Boston LLC holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This represents the total number of active challenges or requests for information from the patent office.
Prosecution for this portfolio is handled by 1 distinct examiner in 1 distinct art unit. The presence of 1 pending office action across a single examiner suggests a highly centralized examination process. This structure allows for a focused approach to the specific technical standards of the 1 distinct art unit assigned.
JOHANSEN, PETER N. is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner manages all current pending matters for the company. Effective prosecution will require navigating the specific requirements of this examiner, who is the sole official currently reviewing the company's 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026063 | DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY | JOHANSEN, PETER N. | 20d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026063 | DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY | JOHANSEN, PETER N. | 20d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18026063 | DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY | JOHANSEN, PETER N. | 1644 | §103§112 | Non-Final OA | 20d | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial